DVYSR logo

Devyser Diagnostics AB (publ) Stock Price

OM:DVYSR Community·SEK 1.6b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 10 Fair Values set on narratives written by author

DVYSR Share Price Performance

SEK 95.10
-32.40 (-25.41%)
SEK 156.12
Fair Value
SEK 95.10
-32.40 (-25.41%)
39.1% undervalued intrinsic discount
SEK 156.12
Fair Value
Price SEK 95.10
AnalystConsensusTarget SEK 156.12

DVYSR Community Narratives

AnalystConsensusTarget·
Fair Value SEK 156.12 39.1% undervalued intrinsic discount

Transplant And Prenatal Testing Expansion Will Drive Strong Long Term Market Position

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
SEK 156.12
39.1% undervalued intrinsic discount
Revenue
35.52% p.a.
Profit Margin
28.99%
Future PE
17.59x
Price in 2028
SEK 181.67

Trending Discussion

Updated Narratives

DVYSR logo

Transplant And Prenatal Testing Expansion Will Drive Strong Long Term Market Position

Fair Value: SEK 156.12 39.1% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Exceptional growth potential and undervalued.

0 Risks
3 Rewards

Devyser Diagnostics AB (publ) Key Details

SEK 250.5m

Revenue

SEK 48.6m

Cost of Revenue

SEK 201.9m

Gross Profit

SEK 210.3m

Other Expenses

-SEK 8.4m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Mar 25, 2026
-0.50
80.60%
-3.35%
0.08%
View Full Analysis

About DVYSR

Founded
2004
Employees
116
CEO
Jan Wahlstrom
WebsiteView website
devyser.com

Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as accessories. Its products are used for targeted cancer treatment to diagnosis genetic diseases and transplant patient follow-up. The company also provides software programs for data processing and analysis, as well as interpretation of test results; and Amplicon Suite and Advyser software programs to screen markers and follow up samples for the same patient. Devyser Diagnostics AB (publ) was incorporated in 2004 and is based in Årsta, Sweden.

Recent DVYSR News & Updates

Earnings Update: Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts

Feb 15
Earnings Update: Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts

Recent updates

No updates